Last reviewed · How we verify
Metfomin plus Simvastatin
Metfomin plus Simvastatin is a Small molecule drug developed by Fasa University of Medical Sciences. It is currently FDA-approved.
Metformin is a small molecule used to treat Polycystic Ovary Syndrome (PCOS), and it has been studied in combination with Simvastatin, a small molecule with the synonyms Simvastatin Acid, Simvastatin Carboxylic Acid, and Simvastatin Hydroxy Acid. A completed study (NCT01021579) investigated the effects of Metformin plus Simvastatin on PCOS in a prospective, randomized, double-blind, placebo-controlled study.
At a glance
| Generic name | Metfomin plus Simvastatin |
|---|---|
| Sponsor | Fasa University of Medical Sciences |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metfomin plus Simvastatin CI brief — competitive landscape report
- Metfomin plus Simvastatin updates RSS · CI watch RSS
- Fasa University of Medical Sciences portfolio CI
Frequently asked questions about Metfomin plus Simvastatin
What is Metfomin plus Simvastatin?
Who makes Metfomin plus Simvastatin?
What development phase is Metfomin plus Simvastatin in?
Related
- Manufacturer: Fasa University of Medical Sciences — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing